Evidence map›Paper›PMID 29636119›Full record

ArticleEpidemiology and infection2018

HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities.

K A Bosh, J R Coyle, V Hansen, E M Kim, S Speers, M Comer, L M Maddox, S Khuwaja, W Zhou, A Jatta and 26 more

Abstract read
In one paragraph

Article in Epidemiology and infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Liver disease in people living with HIV infection: a changing landscape.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. A long-acting 3TC ProTide nanoformulation suppresses HBV replication in humanized mice.Nanomedicine : nanotechnology, biology, and medicine · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

K A BoshDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
J R CoyleBureau of Epidemiology and Population Health, Michigan Department of Health and Human Services, Lansing, Michigan, USA.
V HansenBureau of Epidemiology and Disease Control, Arizona Department of Health Services, Phoenix, Arizona, USA.
E M KimBureau of Epidemiology and Disease Control, Arizona Department of Health Services, Phoenix, Arizona, USA.
S SpeersHIV Surveillance, TB, HIV, STD, and Viral Hepatitis, Connecticut Department of Public Health, Hartford, Connecticut, USA.
M ComerBureau of Communicable Diseases, Florida Department of Health, Tallahassee, Florida, USA.
L M MaddoxBureau of Communicable Diseases, Florida Department of Health, Tallahassee, Florida, USA.
S KhuwajaBureau of Epidemiology, Houston Health Department, Houston, Texas, USA.
W ZhouBureau of Epidemiology, Houston Health Department, Houston, Texas, USA.
A JattaBureau of HIV, STD, and Hepatitis, Iowa Department of Public Health, Des Moines, Iowa, USA.
R MayerBureau of HIV, STD, and Hepatitis, Iowa Department of Public Health, Des Moines, Iowa, USA.
A D BrantleyBureau of Infectious Diseases, Office of Public Health, Louisiana Department of Health, New Orleans, Louisiana, USA.
N W MuriithiBureau of Infectious Diseases, Office of Public Health, Louisiana Department of Health, New Orleans, Louisiana, USA.ORCID https://orcid.org/0000-0003-3765-3403
R BhattacharjeePrevention and Health Promotion Administration, Maryland Department of Health, Baltimore, Maryland, USA.
C FlynnPrevention and Health Promotion Administration, Maryland Department of Health, Baltimore, Maryland, USA.
L BoutonBureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Jamaica Plain, Massachusetts, USA.
B JohnBureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Jamaica Plain, Massachusetts, USA.
J KeuschBureau of Epidemiology and Population Health, Michigan Department of Health and Human Services, Lansing, Michigan, USA.
C A BarberInfectious Disease Epidemiology, Prevention, and Control, Minnesota Department of Health, Saint Paul, Minnesota, USA.
K SweetInfectious Disease Epidemiology, Prevention, and Control, Minnesota Department of Health, Saint Paul, Minnesota, USA.
C RamaswamyBureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene, New York, New York, USA.
E F WestheimerBureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene, New York, New York, USA.
L VanderBuschDivision of Disease Control, North Dakota Department of Health, Bismarck, North Dakota, USA.
A NishimuraPopulation Health Division, San Francisco Department of Public Health, San Francisco, California, USA.
A VuPopulation Health Division, San Francisco Department of Public Health, San Francisco, California, USA.
L Hoffman-ArriagaTexas Department of State Health Services, Austin, Texas, USA.
E RowlinsonTexas Department of State Health Services, Austin, Texas, USA.
A O CarterDivision of Disease Prevention, Virginia Department of Health, Richmond, Virginia, USA.
L E YerkesDivision of Disease Prevention, Virginia Department of Health, Richmond, Virginia, USA.
W LiInfectious Disease Assessment Unit, Washington State Department of Health, Tumwater, Washington, USA.
J R ReuerInfectious Disease Assessment Unit, Washington State Department of Health, Tumwater, Washington, USA.
L J StockmanDivision of Public Health, Wisconsin Department of Health Services, Madison, Wisconsin, USA.
T TangICF International, Inc., Atlanta, Georgia, USA.
J T BrooksDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
E H TeshaleDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
H I HallDivision of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

Coinfection with human immunodeficiency virus (HIV) and viral hepatitis is associated with high morbidity and mortality in the absence of clinical management, making identification of these cases crucial. We examined characteristics of HIV and viral hepatitis coinfections by using surveillance data from 15 US states and two cities. Each jurisdiction used an automated deterministic matching method to link surveillance data for persons with reported acute and chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, to persons reported with HIV infection. Of the 504 398 persons living with diagnosed HIV infection at the end of 2014, 2.0% were coinfected with HBV and 6.7% were coinfected with HCV. Of the 269 884 persons ever reported with HBV, 5.2% were reported with HIV. Of the 1 093 050 persons ever reported with HCV, 4.3% were reported with HIV. A greater proportion of persons coinfected with HIV and HBV were males and blacks/African Americans, compared with those with HIV monoinfection. Persons who inject drugs represented a greater proportion of those coinfected with HIV and HCV, compared with those with HIV monoinfection. Matching HIV and viral hepatitis surveillance data highlights epidemiological characteristics of persons coinfected and can be used to routinely monitor health status and guide state and national public health interventions.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChild, PreschoolCoinfectionFemaleHepatitis, Viral, HumanHIV InfectionsHumansInfantInfant, NewbornMaleMiddle AgedPublic HealthCoinfectionHepatitis BHepatitis CHIV/AIDSPublic Health Surveillance

Identifiers

PMID29636119
PMCPMC5957777

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.